Allegria Therapeutics secures USD 5.1 million Seed extension financing

Basel-based Allegria Therapeutics, a Swiss biotech company focused on treatments for mast cell-mediated diseases, has closed a USD 5.1 million seed extension round. The funding supports progress toward its first clinical candidate and continued advancement of its discovery programs.

Allegria Therapeutics has completed a USD 5.1 million seed extension round to advance its pipeline of mast cell-targeted therapies. The round was led by ALK Abelló, with participation from HighLight Capital (HLC), the Lichtsteiner Foundation and Forty51 Ventures. The financing will allow the company to move its lead program toward pre-clinical candidates and strengthen its early-stage research efforts.

Founded in 2023, Allegria has built a specialist team and advisory board and is developing proprietary methods to selectively modulate mast cells. The company, which has participated in the Venture Leaders Biotech program, has leveraged this international exposure and its scientific strategy to identify molecules with potential for first-in-class therapies addressing allergies and related inflammatory conditions.

ALK-Abelló brings established expertise in allergy treatments to support Allegria’s development plans. The company also works with leading researchers, including Prof. Dr. Martin Metz of Berlin’s Charité and Assoc. Prof. Dr. Philipp Starkl of the Medical University of Vienna. Following the financing, Dr. Peter Sejer Andersen has joined Allegria’s Board as a non-executive director.


Allegria's co-founder and CEO Maria Van Dongen at the Venture Leaders Biotech kick-off in 2024